COVID-19 in solid organ transplant recipients: A single-center case series from Spain.
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.
复制标题
DOI：
10.1111/ajt.15929
复制
发表时间：
2020-07
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
实体器官移植（SOT）后由严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）的临床特征、管理和结局仍然未知。我们报告了我们在2020年3月23日之前在马德里的一家三级护理中心诊断为COVID-19的18名SOT（肾脏[44.4%]，肝脏[33.3%]和心脏[22.2%]）接受者的初步经验。诊断时的中位年龄为71.0 ± 12.8岁，移植后的中位间隔时间为9.3年。发烧（83.3%）和单侧或双侧/多灶性实变形式的放射学异常（72.2%）是最常见的表现。50.0%的患者使用了洛匹那韦/利托那韦（通常与羟氯喹联合使用），其中2例不得不提前停用。其他抗病毒治疗方案包括羟氯喹单药治疗（27.8%）和干扰素-β（16.7%）。截至4月4日，病死率为27.8%（5/18）。在症状发作后中位随访18天后，30.8%（4/13）的幸存者发生了进行性呼吸衰竭，7.7%（1/13）的幸存者临床状况稳定或改善，61.5%（8/13）的幸存者出院回家。C反应蛋白水平在不同的时间点显着较高的受体谁经历了不利的结果。总之，该前线报告表明，SARS-CoV-2感染在SOT接受者中具有严重的病程。
The clinical characteristics, management, and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplant (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%], and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 ± 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine) was used in 50.0% of patients and had to be prematurely discontinued in 2 of them. Other antiviral regimens included hydroxychloroquine monotherapy (27.8%) and interferon-β (16.7%). As of April 4, the case-fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C-reactive protein levels at various points were significantly higher among recipients who experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.
登录
查看更多内容
影响因子：
4.6
作者：
Jain, AB;Venkataramanan, R;Fung, JJ
通讯作者：
Fung, JJ
DOI：
10.1111/j.1469-0691.2011.03537.x
发表时间：
2012-01
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Cordero E;Pérez-Romero P;Moreno A;Len O;Montejo M;Vidal E;Martín-Dávila P;Fariñas MC;Fernández-Sabé N;Giannella M;Pachón J;Novel influenza A(H1N1) Study Group of Spanish Network for Research in Infectious Diseases (REIPI)
通讯作者：
Novel influenza A(H1N1) Study Group of Spanish Network for Research in Infectious Diseases (REIPI)
DOI：
10.1111/1469-0691.12595
发表时间：
2014-09
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Manuel O;López-Medrano F;Keiser L;Welte T;Carratalà J;Cordero E;Hirsch HH;ESCMID Study Group of Infection in Compromised Hosts (ESGICH)
通讯作者：
ESCMID Study Group of Infection in Compromised Hosts (ESGICH)
影响因子：
8.8
作者：
Zhu, Lan;Xu, Xizhen;Chen, Gang
通讯作者：
Chen, Gang
DOI：
10.1016/j.ijantimicag.2020.105949
发表时间：
2020-07-01
影响因子：
10.8
作者：
Gautret, Philippe;Lagier, Jean-Christophe;Raoult, Didier
通讯作者：
Raoult, Didier